Phreesia investors face July 13, 2026 lead plaintiff deadline in securities class action over demand slowdown allegations

Purchasers of Phreesia, Inc. common stock between May 8, 2025 and March 30, 2026 have until July 13, 2026 to seek appointment as lead plaintiff in a proposed securities class action, Rosen Law Firm said. The lawsuit alleges Phreesia made false and misleading statements during the class period and concealed adverse facts about slowing demand and reduced visibility in key revenue streams. According to the complaint, a notable issue was weakened pharmaceutical marketing commitments in the company's Network Solutions segment. The suit claims investors suffered damages when the underlying details entered the market. Rosen said a class action has already been filed and that investors in the proposed class may be entitled to compensation through a contingency fee arrangement without paying out-of-pocket fees or costs. Investors who want to serve as lead plaintiff must move the Court by July 13, 2026. No class has been certified, investors are not represented by counsel unless they retain one, and they may choose their own counsel, remain absent class members, or seek a lead plaintiff role without affecting any potential future recovery.